Literature DB >> 33413350

The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder.

Jessica Heil1,2, Stefan Zajic3, Emily Albertson3, Andrew Brangan3, Iris Jones4, Wendy Roberts3, Michael Sabia4, Elliot Bodofsky4, Alissa Resch3, Rachel Rafeq4, Rachel Haroz4, Russell Buono5, Thomas N Ferraro5, Laura Scheinfeldt3, Matthew Salzman4, Kaitlan Baston4.   

Abstract

BACKGROUND: The opioid use disorder and overdose crisis in the United States affects public health as well as social and economic welfare. While several genetic and non-genetic risk factors for opioid use disorder have been identified, many of the genetic associations have not been independently replicated, and it is not well understood how these factors interact. This study is designed to evaluate relationships among these factors prospectively to develop future interventions to help prevent or treat opioid use disorder.
METHODS: The Genomics of Opioid Addiction Longitudinal Study (GOALS) is a prospective observational study assessing the interplay of genetic and non-genetic by collecting comprehensive genetic and non-genetic information on 400 participants receiving medication for opioid use disorder. Participants will be assessed at four time points over 1 year. A saliva sample will be collected for large-scale genetic data analyses. Non-genetic assessments include validated surveys measuring addiction severity, depression, anxiety, and adverse childhood experiences, as well as treatment outcomes such as urine toxicology results, visit frequency, and number of pre and post-treatment overdoses extracted from electronic medical records. DISCUSSION: We will use these complex data to investigate the relative contributions of genetic and non-genetic risk factors to opioid use disorder and related treatment outcomes.

Entities:  

Keywords:  Addiction; Buprenorphine; Genetics; Medication for opioid use disorder (MOUD); Opioid use disorder (OUD); Substance misuse

Year:  2021        PMID: 33413350      PMCID: PMC7792024          DOI: 10.1186/s12920-020-00837-3

Source DB:  PubMed          Journal:  BMC Med Genomics        ISSN: 1755-8794            Impact factor:   3.063


  37 in total

1.  Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.

Authors:  Kenneth S Kendler; Kristen C Jacobson; Carol A Prescott; Michael C Neale
Journal:  Am J Psychiatry       Date:  2003-04       Impact factor: 18.112

2.  Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients.

Authors:  I T Mahu; P J Conrod; S P Barrett; A Sako; J Swansburg; M Lawrence; F Laroque; J F Morin; A Chinneck; R Nogueira-Arjona; S H Stewart
Journal:  Addict Behav       Date:  2019-07-17       Impact factor: 3.913

Review 3.  Genetics of opiate addiction.

Authors:  Brian Reed; Eduardo R Butelman; Vadim Yuferov; Matthew Randesi; Mary Jeanne Kreek
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

4.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.

Authors:  Lynn R Webster; Rebecca M Webster
Journal:  Pain Med       Date:  2005 Nov-Dec       Impact factor: 3.750

5.  Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015.

Authors:  Rose A Rudd; Puja Seth; Felicita David; Lawrence Scholl
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-12-30       Impact factor: 17.586

Review 6.  A review of opioid addiction genetics.

Authors:  Richard C Crist; Benjamin C Reiner; Wade H Berrettini
Journal:  Curr Opin Psychol       Date:  2018-08-09

7.  A brief measure for assessing generalized anxiety disorder: the GAD-7.

Authors:  Robert L Spitzer; Kurt Kroenke; Janet B W Williams; Bernd Löwe
Journal:  Arch Intern Med       Date:  2006-05-22

8.  OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients.

Authors:  Chi T Viet; Dongmin Dang; Bradley E Aouizerat; Christine Miaskowski; Yi Ye; Dan T Viet; Kentaro Ono; Brian L Schmidt
Journal:  J Pain       Date:  2017-04-27       Impact factor: 5.820

9.  Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City.

Authors:  C Truong; N Krawczyk; M Dejman; S Marshall-Shah; K Tormohlen; D Agus; J Bass
Journal:  Addict Behav       Date:  2019-01-17       Impact factor: 3.913

10.  Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.

Authors:  Jun Ma; Yan-Ping Bao; Ru-Jia Wang; Meng-Fan Su; Mo-Xuan Liu; Jin-Qiao Li; Louisa Degenhardt; Michael Farrell; Frederic C Blow; Mark Ilgen; Jie Shi; Lin Lu
Journal:  Mol Psychiatry       Date:  2018-06-22       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.